A case of new‐onset antibody‐positive myasthenia gravis in a patient treated with pembrolizumab for melanoma

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow et al. · New England Journal of Medicine · 2012 · 8K citations · Full text

Life Sciences, Immunology, Oncology +17

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Scott Antonia, José A. López-Martín, Johanna C. Bendell et al. · The Lancet Oncology · 2016 · 1.3K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +14

Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy

Lisa Zimmer, Simone M. Goldinger, Lars Hofmann et al. · European Journal of Cancer · 2016 · 560 citations

Medicine, Pharmacology, Pharmacotherapy +11

Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma

Bing Liao, Sheetal Shroff, Carlos Kamiya-Matsuoka et al. · Neuro-Oncology · 2014 · 288 citations · Full text

Life Sciences, Immunology, Neurology +17

Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma

T Shirai, Tasuku Sano, Fuminao Kamijo et al. · Japanese Journal of Clinical Oncology · 2015 · 137 citations · Full text

Life Sciences, Immunology, Oncology +17